WO2009051910A1 - Composés ayant une activité augmentant le transport ionique grâce à la cftr mutante et leurs utilisations - Google Patents

Composés ayant une activité augmentant le transport ionique grâce à la cftr mutante et leurs utilisations Download PDF

Info

Publication number
WO2009051910A1
WO2009051910A1 PCT/US2008/075505 US2008075505W WO2009051910A1 WO 2009051910 A1 WO2009051910 A1 WO 2009051910A1 US 2008075505 W US2008075505 W US 2008075505W WO 2009051910 A1 WO2009051910 A1 WO 2009051910A1
Authority
WO
WIPO (PCT)
Prior art keywords
cftr
composition
methyl
substituted
mutant
Prior art date
Application number
PCT/US2008/075505
Other languages
English (en)
Inventor
Mark J. Kurth
Alan Verkman
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2009051910A1 publication Critical patent/WO2009051910A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the present invention relates to potentiator compounds and methods for increasing ion transport by mutant cystic fibrosis transmembrane conductance regulator protein.
  • the heteroaryl groups are those derived from thiazole, thiophen, pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole and pyrazine.
  • Substituted alkynyl includes those groups recited in the definition of "substituted” herein, and particularly refers to an alkynyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, aliphatic, substituted aliphatic, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S
  • “Sulfonyl” refers to the divalent radical -S(O 2 )-. “Substituted sulfonyl” refers to a radical such as R-(O 2 )S- wherein R is any substituent described herein. "Aminosulfonyl” refers to the radical H 2 N(O 2 )S-, and “substituted aminosulfonyl” refers to a radical such as R 2 N(O 2 )S- wherein each R is independently any substituent described herein.
  • Thioalkoxy refers to the group -S-alkyl.
  • Mutant-CFTR activators are usually high-affinity mutant-CFTR activators, e.g., have an affinity for mutant-CFTR of at least about one micromolar, about one to five micromolar, about 200 nanomolar to one micromolar, about 50 nanomolar to 200 nanomolar, or below 50 nanomolar.
  • composition is meant to encompass a composition suitable for administration to a subject, such as a mammal, especially a human.
  • a “pharmaceutical composition” is sterile, and preferably free of contaminants that are capable of eliciting an undesirable response within the subject (e.g., the compound(s) in the pharmaceutical composition is pharmaceutical grade).
  • Pharmaceutical compositions can be designed for administration to subjects or patients in need thereof via a number of different routes of administration including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, intracheal and the like.
  • the composition is suitable for administration by a transdermal route, using a penetration enhancer other than DMSO.
  • the pharmaceutical compositions are suitable for administration by a route other than transdermal administration.
  • protecting group means a chemical group introduced into a molecule by chemical modification of a functional group in order to protect or shield the functional group from its normal chemical reactivity.
  • Protecting groups, their addition and removal are well known (W. Green, P. G. M. Wuts, Protective Groups in Organic Synthesis, Wiley-lnterscience, New York, 2005). Removal of the protecting group generates the original functional group, which may be referred to as an "unprotected group”.
  • a featured aspect of the invention includes compounds of Panel B above in which R 3 is methyl, R 4 is NH or O, and R 1 is selected from hydroxyl, isopropyl, methoxy, trifluormethyl, azide, and dioxane fused to the R 1 -phenyl so as to comprise benzodioxane bonded to R 4 .
  • cells are cultured on plastic in Coon's modified F12 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 pglml streptomycin, and plated on black 96-well microplates (Corning-Costar 3904) at 30,000 cells/well.
  • cells are cultured on Snapwell permeable supports (Coming-Costar) at 500,000 cells/insert.
  • Human nasal epithelium cells from CF patients are cultured on Snapwell inserts and allowed to differentiate in a hormone-supplemented medium (Galietta et al., Am. J. Physiol., 275: 19723- 19728 (1 998)).
  • Assay of cAMP cAMP activity is measured using the BIOTRAK enzymatic immunoassay (Arnersham) of FRT cell lysates after incubation with the compounds for 10 minutes in the presence of 0.5 pM forskolin.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des compositions, des préparations pharmaceutiques et des procédés pour augmenter l'activité d'une protéine mutante régulatrice de la conductance transmembranaire de la mucoviscidose (mutant-CFTR). Les compositions, préparations pharmaceutiques et procédés sont utiles pour l'étude et le traitement de troubles associés à la mutant-CFTR, tels que la mucoviscidose. Les compositions et préparations pharmaceutiques de l'invention peuvent comprendre un ou des composés contenant de la phénylglycine de l'invention, ou un analogue ou dérivé de ceux-ci.
PCT/US2008/075505 2007-10-16 2008-09-05 Composés ayant une activité augmentant le transport ionique grâce à la cftr mutante et leurs utilisations WO2009051910A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98038707P 2007-10-16 2007-10-16
US60/980,387 2007-10-16

Publications (1)

Publication Number Publication Date
WO2009051910A1 true WO2009051910A1 (fr) 2009-04-23

Family

ID=40259994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/075505 WO2009051910A1 (fr) 2007-10-16 2008-09-05 Composés ayant une activité augmentant le transport ionique grâce à la cftr mutante et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2009051910A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012036573A2 (fr) 2010-09-14 2012-03-22 Instytut Biochemii I Biofizyki Pan Composés modulateurs d'une protéine cftr mutante et leur utilisation pour le traitement de maladies associées à un dysfonctionnement de la protéine cftr
WO2014086687A1 (fr) 2012-12-03 2014-06-12 Universita' Degli Studi Di Padova Correcteur de cftr pour le traitement de troubles génétiques affectant le muscle strié
CN104592163A (zh) * 2015-01-08 2015-05-06 爱斯特（成都）生物制药有限公司 一种手性2-苯基吡咯烷的合成方法
US9073863B2 (en) 2011-05-27 2015-07-07 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof
US20180194802A1 (en) * 2012-01-19 2018-07-12 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US10689414B2 (en) 2013-07-25 2020-06-23 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055106A2 (fr) * 2000-01-28 2001-08-02 Melacure Therapeutics Ab Nouveaux agonistes et antagonistes de recepteurs des melanocortines
WO2002074730A1 (fr) * 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibiteurs de l'integrine $g(a)v$g(b)¿6?
WO2005120497A2 (fr) * 2004-06-04 2005-12-22 The Regents Of The University Of California Composes intervenant dans l'acceleration du transport ionique par le cftr mutant, et utilisations desdits composes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055106A2 (fr) * 2000-01-28 2001-08-02 Melacure Therapeutics Ab Nouveaux agonistes et antagonistes de recepteurs des melanocortines
WO2002074730A1 (fr) * 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibiteurs de l'integrine $g(a)v$g(b)¿6?
WO2005120497A2 (fr) * 2004-06-04 2005-12-22 The Regents Of The University Of California Composes intervenant dans l'acceleration du transport ionique par le cftr mutant, et utilisations desdits composes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NICOLETTA PEDEMONTE ET AL: "Phenylglycine and sulfonamide correctors of defective DeltatF508and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 67, no. 5, 1 May 2005 (2005-05-01), pages 1797 - 1807, XP002492468, ISSN: 0026-895X *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012036573A2 (fr) 2010-09-14 2012-03-22 Instytut Biochemii I Biofizyki Pan Composés modulateurs d'une protéine cftr mutante et leur utilisation pour le traitement de maladies associées à un dysfonctionnement de la protéine cftr
CN103228632A (zh) * 2010-09-14 2013-07-31 波兰科学院生物化学与生物物理研究所 作为突变cftr蛋白的调节剂的化合物及其在治疗与cftr蛋白失常相关的疾病中的用途
CN103228632B (zh) * 2010-09-14 2016-08-31 波兰科学院生物化学与生物物理研究所 作为突变cftr蛋白的调节剂的化合物及其在治疗与cftr蛋白失常相关的疾病中的用途
EP2816034A2 (fr) 2010-09-14 2014-12-24 Instytut Biochemii I Biofizyki Polskiej Akademii Nauk Composés modulateurs d'une protéine CFTR mutante et leur utilisation pour le traitement de maladies associées à un dysfonctionnement de la protéine CFTR
EP2816035A2 (fr) 2010-09-14 2014-12-24 Instytut Biochemii I Biofizyki Polskiej Akademii Nauk Composés modulateurs d'une protéine CFTR mutante et leur utilisation pour le traitement de maladies associées à un dysfonctionnement de la protéine CFTR
EP2826771A2 (fr) 2010-09-14 2015-01-21 Instytut Biochemii I Biofizyki Polskiej Akademii Nauk Composés en tant que modulateurs de la protéine CFTR mutante et leur utilisation pour traiter des maladies associées à un dysfonctionnement de la protéine CFTR
CN104496840A (zh) * 2010-09-14 2015-04-08 波兰科学院生物化学与生物物理研究所 作为突变cftr蛋白的调节剂的化合物及其在治疗与cftr蛋白失常相关的疾病中的用途
US9073863B2 (en) 2011-05-27 2015-07-07 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof
US20180194802A1 (en) * 2012-01-19 2018-07-12 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US10640534B2 (en) * 2012-01-19 2020-05-05 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US10717764B2 (en) 2012-01-19 2020-07-21 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US11667673B2 (en) 2012-01-19 2023-06-06 Servier Pharmaceuticals Llc Therapeutically active compounds and their methods of use
WO2014086687A1 (fr) 2012-12-03 2014-06-12 Universita' Degli Studi Di Padova Correcteur de cftr pour le traitement de troubles génétiques affectant le muscle strié
US10689414B2 (en) 2013-07-25 2020-06-23 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US11021515B2 (en) 2013-07-25 2021-06-01 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN104592163A (zh) * 2015-01-08 2015-05-06 爱斯特（成都）生物制药有限公司 一种手性2-苯基吡咯烷的合成方法
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies

Similar Documents

Publication Publication Date Title
US7939558B2 (en) Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US7696244B2 (en) Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US8143295B2 (en) Compounds having activity in correcting mutant-CFTR processing and uses thereof
US8389736B2 (en) Compounds having activity in correcting mutant-CFTR processing and uses thereof
EP1085848B1 (fr) Inhibiteurs du facteur de transcription nf-kappa b
WO2009051910A1 (fr) Composés ayant une activité augmentant le transport ionique grâce à la cftr mutante et leurs utilisations
CA2736441A1 (fr) Pyrazolylthiazoles en tant que correcteurs du regulateur de la conductivite transmembranaire de la proteine .delta.f508 de la fibrose kystique
EP4108664A1 (fr) Forme cristalline d'inhibiteur de jak et son application
JP2021191804A (ja) 二重ｐｉ３ｋデルタ‐ガンマキナーゼ阻害剤及びコルチコステロイドを含む治療方法及び組成物
JP6748704B2 (ja) 抗癌治療剤
WO2012166654A1 (fr) Composés de cyanoquinoléine ayant une activité pour corriger le traitement de la protéine cftr mutante et augmenter le transport ionique et les utilisations de ceux-ci
JP2021524853A (ja) ハンチントン病を治療するのに使用するための薬学的化合物
NZ766879B2 (en) Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid
NZ729419B2 (en) Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid
JP2014141472A (ja) １，３，５−トリアジン誘導体を有する線維化予防又は治療剤
EP1704862A1 (fr) Derivés de la 2,5-bis (tetrahydroxybutyl) pyrazine pour le traitement de l'ostéoarthrite et de la polyarthrite rhumatoïde
JPH11511138A (ja) 酸化窒素シンターゼ（ｎｏｓ）阻害剤
MXPA00012498A (en) INHIBITORS OF TRANSCRIPTION FACTOR NF-&kgr;B

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08799278

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08799278

Country of ref document: EP

Kind code of ref document: A1